← Back to Search

Immunomodulator

Orencia (Abatacept) for Sjogren's Syndrome

Phase 2
Waitlist Available
Research Sponsored by Arthritis & Rheumatism Associates, P.C.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Subjects diagnosed with Sjogren's Syndrome
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 32 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial is testing Orencia, a drug that reduces immune system activity, in patients with Sjogren's Syndrome. The goal is to see if it can help reduce inflammation and damage in their salivary glands.

Eligible Conditions
  • Sjogren's Syndrome

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Salivary gland changes

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Orencia (Abatacept)Active Control1 Intervention
Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
Group II: PlaceboPlacebo Group1 Intervention
Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)

Find a Location

Who is running the clinical trial?

Arthritis & Rheumatism Associates, P.C.Lead Sponsor
2 Previous Clinical Trials
300 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,681 Previous Clinical Trials
4,124,964 Total Patients Enrolled
8 Trials studying Sjogren's Syndrome
1,626 Patients Enrolled for Sjogren's Syndrome
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top